Latest Headlines
-
Eisai Announces Move To Solo Development And Commercialization Of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC)
7/1/2024
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin (FZEC), formerly known as MORAb-202, a folate receptor alpha (FRα)-targeting antibody drug conjugate (ADC) due to ongoing portfolio prioritization efforts within Bristol Myers Squibb.
-
SCG Cell Therapy Announces FDA IND Clearance Of SCG142, A Next-Generation HPV-Specific TCR T Cell Therapy For Patients With HPV-Associated Solid Tumors
6/30/2024
SCG Cell Therapy Pte Ltd (SCG), a biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, today announced that U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to initiate Phase 1/2 clinical trial for SCG142, a novel next-generation human papillomavirus (HPV) E7-specific T-cell receptor-engineered T (TCR T) cell therapy for patients with HPV-associated solid tumors.
-
Soleno Therapeutics Announces Submission Of New Drug Application To The U.S. FDA For DCCR (Diazoxide Choline) Extended-Release Tablets For The Treatment Of Prader-Willi Syndrome
6/28/2024
Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia.
-
Psylo Partnership To Deliver Psychedelic Treatments For Mental Health
6/27/2024
The University of Sydney’s Brain and Mind Centre has partnered with Psylo, a global biotechnology startup and pioneer in non-hallucinogenic psychedelic drugs, to develop innovative treatments for psychiatric and neurological disorders using advanced artificial intelligence technologies.
-
Scientists Use Computational Modeling To Guide A Difficult Chemical Synthesis
6/27/2024
Researchers from MIT and the University of Michigan have discovered a new way to drive chemical reactions that could generate a wide variety of compounds with desirable pharmaceutical properties.
-
ELRIG UK And The Protein Society Partner To Advance Protein Sciences In Drug Discovery
6/26/2024
The European Laboratory Research & Innovation Group (ELRIG) UK, a not-for-profit, volunteer-led organisation for the drug discovery community, has partnered with The Protein Society (TPS), an international, not-for-profit, scholarly society, with the mission to provide forums for the advancement of research into protein structure, function, design and applications.
-
Concerto Biosciences Receives FDA Investigational New Drug Clearance For Live Biotherapeutic Product To Treat Atopic Dermatitis
6/26/2024
Concerto Biosciences, a Cambridge-based biotechnology company, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 1, first-in-human trial of Ensemble No.2 (ENS-002), an investigational live biotherapeutic product (LBP) to treat atopic dermatitis (AD).
-
Vir Biotechnology Receives FDA IND Clearance And Fast Track Designation For Tobevibart And Elebsiran For The Treatment Of Chronic Hepatitis Delta Infection
6/26/2024
Vir Biotechnology, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application and granted Fast Track designation for the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta infection.
-
Hyundai Bioscience Succeeds In Developing 'Multi-Treatment For Mosquito-Borne Viral Infections' Including Dengue Fever
6/25/2024
Hyundai Bioscience (CEO Oh Sang-gi), which is preparing for a dengue fever basket clinical trial in Brazil, announced on the 24th that it has successfully developed a 'multi-treatment drug for mosquito-borne viral infections, including dengue fever,' using niclosamide as the main ingredient.
-
Cure And The New York Academy Of Sciences To Co-Host Forum On Science And Business Of AI-Driven Drug Discovery
6/24/2024
Cure.®, a healthcare innovation campus in New York City, and The New York Academy of Sciences, an organization committed to advancing science and technology for the benefit of society, today announced an exciting two-part science technology seminar: Science and Business of AI-Driven Drug Discovery and Deepfakes & Democracy in the Age of AI.